170 related articles for article (PubMed ID: 37460393)
21. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer.
Shen Q; Xu Z; Xu S
Int J Oncol; 2020 Oct; 57(4):967-979. PubMed ID: 32945379
[TBL] [Abstract][Full Text] [Related]
22. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
Wang L; Shang X; Feng Q
Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
[TBL] [Abstract][Full Text] [Related]
23. BIBR1532, a Selective Telomerase Inhibitor, Enhances Radiosensitivity of Non-Small Cell Lung Cancer Through Increasing Telomere Dysfunction and ATM/CHK1 Inhibition.
Ding X; Cheng J; Pang Q; Wei X; Zhang X; Wang P; Yuan Z; Qian D
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):861-874. PubMed ID: 31419512
[TBL] [Abstract][Full Text] [Related]
24. Up-regulation of long non-coding RNA PANDAR is associated with poor prognosis and promotes tumorigenesis in bladder cancer.
Zhan Y; Lin J; Liu Y; Chen M; Chen X; Zhuang C; Liu L; Xu W; Chen Z; He A; Zhang Q; Sun X; Zhao G; Huang W
J Exp Clin Cancer Res; 2016 May; 35(1):83. PubMed ID: 27206339
[TBL] [Abstract][Full Text] [Related]
25. Low expression of long noncoding RNA PANDAR predicts a poor prognosis of non-small cell lung cancer and affects cell apoptosis by regulating Bcl-2.
Han L; Zhang EB; Yin DD; Kong R; Xu TP; Chen WM; Xia R; Shu YQ; De W
Cell Death Dis; 2015 Feb; 6(2):e1665. PubMed ID: 25719249
[TBL] [Abstract][Full Text] [Related]
26. LncRNA SNHG12 Decreases Non-Small Cell Lung Cancer Cell Sensitivity to Cisplatin by Repressing miR-525-5p and Promoting XIAP.
Tan D; Wang S; Zhang P; Peng C; Wu T
Ann Clin Lab Sci; 2023 Jan; 53(1):64-75. PubMed ID: 36889771
[TBL] [Abstract][Full Text] [Related]
27. Cucurbitacin B suppresses hepatocellular carcinoma progression through inducing DNA damage-dependent cell cycle arrest.
Li QZ; Chen YY; Liu QP; Feng ZH; Zhang L; Zhang H
Phytomedicine; 2024 Apr; 126():155177. PubMed ID: 38412667
[TBL] [Abstract][Full Text] [Related]
28. LncRNA PANDAR regulates the G1/S transition of breast cancer cells by suppressing p16(INK4A) expression.
Sang Y; Tang J; Li S; Li L; Tang X; Cheng C; Luo Y; Qian X; Deng LM; Liu L; Lv XB
Sci Rep; 2016 Mar; 6():22366. PubMed ID: 26927017
[TBL] [Abstract][Full Text] [Related]
29. Exosomal circ_PIP5K1A regulates the progression of non-small cell lung cancer and cisplatin sensitivity by miR-101/ABCC1 axis.
Shao N; Song L; Sun X
Mol Cell Biochem; 2021 Jun; 476(6):2253-2267. PubMed ID: 33570734
[TBL] [Abstract][Full Text] [Related]
30. Knockdown of lncRNA DLX6-AS1 inhibits cell proliferation, migration and invasion while promotes apoptosis by downregulating PRR11 expression and upregulating miR-144 in non-small cell lung cancer.
Huang Y; Ni R; Wang J; Liu Y
Biomed Pharmacother; 2019 Jan; 109():1851-1859. PubMed ID: 30551440
[TBL] [Abstract][Full Text] [Related]
31. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.
Chen P; Li J; Chen YC; Qian H; Chen YJ; Su JY; Wu M; Lan T
Cell Oncol (Dordr); 2016 Dec; 39(6):511-522. PubMed ID: 27473273
[TBL] [Abstract][Full Text] [Related]
32. The high expression of long non-coding RNA PANDAR indicates a poor prognosis for colorectal cancer and promotes metastasis by EMT pathway.
Lu M; Liu Z; Li B; Wang G; Li D; Zhu Y
J Cancer Res Clin Oncol; 2017 Jan; 143(1):71-81. PubMed ID: 27629879
[TBL] [Abstract][Full Text] [Related]
33. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of DNA‑PK activity sensitizes A549 cells to X‑ray irradiation by inducing the ATM‑dependent DNA damage response.
Yang L; Yang X; Tang Y; Zhang D; Zhu L; Wang S; Wang B; Ma T
Mol Med Rep; 2018 Jun; 17(6):7545-7552. PubMed ID: 29620203
[TBL] [Abstract][Full Text] [Related]
35. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
[TBL] [Abstract][Full Text] [Related]
36. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
[TBL] [Abstract][Full Text] [Related]
37. LncRNA ITGB2-AS1 promotes cisplatin resistance of non-small cell lung cancer by inhibiting ferroptosis via activating the FOSL2/NAMPT axis.
Chen H; Wang L; Liu J; Wan Z; Zhou L; Liao H; Wan R
Cancer Biol Ther; 2023 Dec; 24(1):2223377. PubMed ID: 37370246
[TBL] [Abstract][Full Text] [Related]
38. ARRB1 enhances the chemosensitivity of lung cancer through the mediation of DNA damage response.
Shen H; Wang L; Zhang J; Dong W; Zhang T; Ni Y; Cao H; Wang K; Li Y; Wang Y; Du J
Oncol Rep; 2017 Feb; 37(2):761-767. PubMed ID: 28035404
[TBL] [Abstract][Full Text] [Related]
39. MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer.
Okita R; Yukawa T; Nojima Y; Maeda A; Saisho S; Shimizu K; Nakata M
Cancer Immunol Immunother; 2016 May; 65(5):499-509. PubMed ID: 26940474
[TBL] [Abstract][Full Text] [Related]
40. Knockdown of LncRNA PVT1 inhibits tumorigenesis in non-small-cell lung cancer by regulating miR-497 expression.
Guo D; Wang Y; Ren K; Han X
Exp Cell Res; 2018 Jan; 362(1):172-179. PubMed ID: 29133127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
